CD4 and neoplasm: Flow cytometry analysis of tumor tissues revealed a remarkable enhancement in antitumor immunity under HMCZH treatment compared to PBS control: mature DCs increased from 6.17% to 28.9%, intratumoral CD8+ T cells rose from 2.88% to 8.78%, and CD4+ T cells expanded from 2.56% to 13.9%.